AstraZeneca said on Monday it had won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine.
Tagrisso is designed to help cancer patients with certain genetic mutations that are very common in China and other parts of east Asia, reports Reuters.
